Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Real World Superiority Data May Not Be Enough To Boost GSK's Breo In COPD

Executive Summary

Breo Ellipta is associated with a lower rate of exacerbations in real world Salford study, but some analysts question whether it's too late to turn performance around in a highly competitive, highly price-conscious market.

Advertisement

Related Content

Relvar/Breo “Real World” Asthma Benefits Help GSK – But Can't Remove Generic Threat
GSK Leads Way With Real World Data, But Others Follow
GSK’s Breo Fails To Reach Peak In SUMMIT Survival Study
“Real-World” Breo Study: A Q&A With GSK’s David Leather

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel